TQ Therapeutics GmbH (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Bristol Myers Squibb's Juno Therapeutics division, through a share purchase agreement announced in May 2025. The financial terms of the acquisition were not disclosed.
The strategic acquisition significantly expands TQx's cell therapy capabilities by providing access to intellectual property and licensing agreements that will support the development of the company's decentralized cell processing platform. Juno GmbH previously operated as part of Bristol Myers Squibb's European cell therapy portfolio.
Advancing Decentralized Cell Therapy Manufacturing
TQx is focused on transforming traditional cell therapy production toward a decentralized, scalable, and highly automated platform. The company is developing a bedside-compatible system designed to reduce production times and improve scalability in extracorporeal cell therapy, moving away from centralized manufacturing infrastructure toward on-site processing.
"This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future," said Dr. Christian Eckert, CEO of TQx. "This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients."
Platform Technology and Accessibility Goals
The acquisition enables TQx to accelerate development of its ultra-short cell and gene therapy (CGT) platform, which is designed to deliver individualized therapies with reduced logistical and operational burden. The company's platform aims to make advanced therapies more accessible and cost-effective by broadening access to CGT treatments across a wider range of healthcare settings.
TQx's approach focuses on decentralizing, scaling, automating, and expediting the cell therapy development and production process. By achieving these goals, the company hopes to make life-changing cell and gene therapies more accessible to patients worldwide.
The deal forms part of TQx's broader strategy to advance technologies that expand access to cell and gene therapy treatments. TQx has not disclosed specific operational integration plans following the acquisition of Juno GmbH.
